DAJY(SZ:002030)2022-04-29 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥3,362,176,107.47, representing a 43.69% increase compared to ¥2,339,884,957.72 in the same period last year[6] - Net profit attributable to shareholders for Q1 2022 was ¥1,679,951,294.17, up 48.85% from ¥1,128,623,209.01 in the previous year[6] - The net profit after deducting non-recurring gains and losses was ¥1,667,947,149.90, reflecting a 49.86% increase from ¥1,112,981,665.53 year-on-year[6] - Basic earnings per share for Q1 2022 were ¥1.1970, an increase of 48.84% from ¥0.8042 in the previous year[6] - Total tax payable increased by 64.22% to ¥668,415,715.48, attributed to higher operating revenue[18] - The total comprehensive income for the current period was ¥1,690,303,553.03, compared to ¥1,134,776,587.05 in the previous period, reflecting a growth of about 49.0%[46] Cash Flow - The net cash flow from operating activities was ¥839,383,630.81, which is a 21.29% increase compared to ¥692,043,744.56 in the same period last year[6] - Operating cash flow generated from operating activities amounted to ¥839,383,630.81, an increase of 21.3% compared to ¥692,043,744.56 in the previous period[49] - Cash inflow from investment activities totaled ¥523,980,893.91, a decrease of 42.0% from ¥903,192,865.94 in the previous period[51] - Net cash flow from financing activities was -¥26,494,506.77, compared to -¥133,731,670.65 in the previous period, indicating an improvement[51] - Total cash outflow from operating activities was ¥2,132,451,712.30, an increase of 73.3% from ¥1,230,421,124.68 in the previous period[49] Assets and Liabilities - Total assets at the end of Q1 2022 reached ¥12,559,021,215.95, marking a 21.50% increase from ¥10,336,444,131.31 at the end of the previous year[6] - The company's total current assets amounted to CNY 7,601,347,585.97, up from CNY 5,984,980,388.61, indicating an increase of about 27%[32] - The total liabilities of the company were CNY 3,208,747,814.37, up from CNY 2,676,474,181.92, which is an increase of approximately 19.8%[36] - The company's equity attributable to shareholders was ¥9,031,388,111.14, which is a 22.85% increase from the previous year[9] Operational Metrics - Accounts receivable increased by 49.30% to ¥3,373,712,388.85 from ¥2,259,665,605.15 year-on-year, driven by increased operating revenue[15] - The company reported a 30.81% increase in prepayments, totaling ¥238,842,094.33 compared to ¥182,589,388.68 in the previous year, due to increased business volume[15] - Accounts payable rose by 48.26% to ¥819,884,449.27 from ¥553,009,648.58, reflecting increased business activity[15] - Cash received from the sale of goods and services was ¥2,553,446,552.78, compared to ¥1,727,739,339.40 in the previous period, reflecting a growth of 47.8%[49] Research and Development - Research and development expenses surged by 97.46% to ¥119,790,428.09, indicating a stronger focus on innovation[18] - Research and development expenses rose to ¥119,790,428.09 from ¥60,666,828.78, indicating an increase of approximately 97.2%[43] Other Financial Metrics - The company reported a credit impairment loss of -¥51,276,230.93, a 157.54% increase, linked to higher revenue[18] - Other income decreased by 54.35% to ¥11,061,853.30, primarily due to reduced government subsidies compared to the previous year[18] - The company has no asset impairment losses reported during the period, marking a 100% decrease from the previous year[18] - The company reported a net investment income of ¥63,160,614.43, up from ¥52,057,966.18, indicating an increase of approximately 21.4%[43] Future Outlook - The company plans to continue expanding its business operations and exploring new strategies for growth in the upcoming quarters[30] - The company has obtained a medical device registration certificate, indicating progress in new product development[30]